Abstract
Objective To determine the metabolic and reproductive effectiveness of rosiglitazone in polycystic ovary syndrome (PCOS).
Setting Academic clinical practice and General Clinical Research Center.
PATIENT(S): A 25-year-old woman with PCOS.
INTERVENTION(S): Rosiglitazone maleate, 4 mg daily for 5 months until conception.
MAIN OUTCOME MEASURE(S): Insulin sensitivity by steady-state plasma glucose technique; serum androgens, progesterone, and hCG; and pelvic ultrasound images.
RESULT(S): Rosiglitazone treatment for 5 months improved insulin sensitivity, lowered serum free testosterone, and resulted in spontaneous ovulation and conception.
CONCLUSION(S): Rosiglitazone is a promising insulin sensitizer for treatment of PCOS. Clinical trials are warranted.
rosiglitazone pcos ovulation induction, insulin sensitizers polycystic ovary syndrome, thiazolidinedione fertility treatment pcos, insulin resistance pcos pregnancy, metabolic treatment pcos spontaneous ovulation, rosiglitazone hyperandrogenism treatment, insulin sensitivity pcos conception, root cause pcos treatment ovulation, thiazolidinediones anovulation therapy, pcos insulin sensitizer case report
Keywords
Adult, Female, Humans, Hypoglycemic Agents/therapeutic Use, Insulin/physiology, Ovulation, Polycystic Ovary Syndrome/drug Therapy/physiopathology, Pregnancy, Rosiglitazone, Thiazoles/therapeutic Use, Thiazolidinediones, Hypoglycemic Agents, Insulin, Thiazoles, Thiazolidinediones, Rosiglitazone,